These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3817281)

  • 21. Rifaximin for the treatment of hepatic encephalopathy.
    Mullen K; Prakash R
    Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
    Adachi JA; DuPont HL
    Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hepatic encephalopathy. Rifaximin opens new perspectives].
    MMW Fortschr Med; 2014 Jul; 156(13):78-9. PubMed ID: 25318235
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin.
    Di Stefano M; Corazza GR
    Chemotherapy; 2005; 51 Suppl 1():103-9. PubMed ID: 15855754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: the current pharmacological therapies for hepatic encephalopathy.
    Bass NM
    Aliment Pharmacol Ther; 2007 Feb; 25 Suppl 1():23-31. PubMed ID: 17295849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rifaximin (Xifaxan 550) for hepatic encephalopathy.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):87. PubMed ID: 21045761
    [No Abstract]   [Full Text] [Related]  

  • 27. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
    Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intestine specific broad spectrum antibiotic. Rifaximin: therapy option in hepatic encephalopathy].
    MMW Fortschr Med; 2014 Feb; 156(3):64-5. PubMed ID: 24938070
    [No Abstract]   [Full Text] [Related]  

  • 31. Infectious diarrhea in the aged: controlled clinical trial of rifaximin.
    Della Marchina M; Renzi G; Palazzini E
    Chemioterapia; 1988 Oct; 7(5):336-40. PubMed ID: 3066519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.
    Lauritano EC; Gabrielli M; Lupascu A; Santoliquido A; Nucera G; Scarpellini E; Vincenti F; Cammarota G; Flore R; Pola P; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2005 Jul; 22(1):31-5. PubMed ID: 15963077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
    Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
    Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intestinal bacterial overgrowth during chronic pancreatitis.
    Trespi E; Ferrieri A
    Curr Med Res Opin; 1999; 15(1):47-52. PubMed ID: 10216811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifaximin: new therapeutic indication and future directions.
    Rivkin A; Gim S
    Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxic epidermal necrolysis associated with rifaximin.
    Patel AS; Supan EM; Ali SN
    Am J Health Syst Pharm; 2013 May; 70(10):874-6. PubMed ID: 23640348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins.
    Cacciottolo TM; Kingdon A; Alexander GJ
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1765. PubMed ID: 24703862
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment options for hepatic encephalopathy.
    Schiano TD
    Pharmacotherapy; 2010 May; 30(5 Pt 2):16S-21S. PubMed ID: 20412036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifaximin pharmacology and clinical implications.
    Ojetti V; Lauritano EC; Barbaro F; Migneco A; Ainora ME; Fontana L; Gabrielli M; Gasbarrini A
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):675-82. PubMed ID: 19442033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.